Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study

The Journal of Antimicrobial Chemotherapy
So-Youn ParkSung-Han Kim

Abstract

We performed a prospective observational study comparing the efficacy and safety of low-dose ganciclovir (5 mg/kg/day) as initial preemptive therapy in allogeneic haematopoietic stem cell transplantation (HSCT) recipients with conventional-dose ganciclovir (10 mg/kg/day). All adult patients undergoing allogeneic HSCT were enrolled at a transplant centre over a 24 month period. The decision to use low-dose or conventional-dose ganciclovir was at the discretion of each attending haematologist. A logistic regression model with inverse probability of treatment weighting (IPTW) using propensity scores was performed to reduce the effect of the selection bias in assignment for ganciclovir preemptive therapy. Of the 252 HSCT recipients, 97 (38%) received preemptive ganciclovir therapy. Of these, 53 (55%) and 44 (45%) received low-dose and conventional-dose ganciclovir, respectively. The viral clearance rate was higher in the low-dose ganciclovir group [98% (52/53)] than in the conventional-dose ganciclovir group [86% (38/44), P = 0.04], while the low-dose ganciclovir group exhibited a longer viral clearance time (median 21.0 days) than the conventional-dose ganciclovir group (median 14.0 days, P = 0.05). The rate of discontinuation of ...Continue Reading

References

Feb 1, 1993·Annals of Internal Medicine·J M GoodrichJ D Meyers
Aug 24, 2000·Epidemiology·J M RobinsB Brumback
Jan 30, 2002·The Journal of Antimicrobial Chemotherapy·Paul D Griffiths
Mar 27, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Per LjungmanCarlos Paya
Jan 10, 2003·Statistics in Medicine·Ralph B D'AgostinoLisa M Sullivan
Mar 21, 2009·Blood·Michael Boeckh, Per Ljungman
May 16, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eun-Young JangSung-Han Kim
May 15, 2010·Infectious Disease Clinics of North America·Per LjungmanMichael Boeckh
Jun 11, 2011·The Journal of Clinical Investigation·Michael Boeckh, Adam P Geballe
Jul 1, 2011·The Korean Journal of Internal Medicine·Dong-Gun LeeJung-Hyun Choi

❮ Previous
Next ❯

Citations

Apr 5, 2016·Expert Review of Hematology·Enrico MaffiniBenedetto Bruno
Apr 5, 2016·Transplant Infectious Disease : an Official Journal of the Transplantation Society·H Y JuH S Ahn
Nov 1, 2016·Expert Review of Hematology·Franco LocatelliPietro Merli
Aug 25, 2019·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Wei LuFu-Der Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.